The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
A pyrrolopyridine that is 1H-pyrrolo[2,3-b]pyridine which is substituted at position 5 by a p-chlorophenyl group and at positions 3 by a 3-amino-2,6-difluorobenzoyl group, the amino group of which has undergone formal condensation with propane-1-sulfonic acid to give the corresponding sulfonamide. An inhibitor of BRAF and other kinases.
[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACACA mRNA; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACACA mRNA]
[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACLY mRNA; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACLY mRNA]
[BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BBC3 protein; [MET protein affects the susceptibility to HGF protein] affects the reaction [[BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BBC3 protein]
[BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BCL2L11 protein; [MET protein affects the susceptibility to HGF protein] affects the reaction [[BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BCL2L11 protein]
Vemurafenib results in decreased activity of BRAF protein; Vemurafenib results in decreased activity of BRAF protein mutant form BRAF protein affects the susceptibility to Vemurafenib [BRAF protein affects the susceptibility to Vemurafenib] which affects the cleavage of SREBF1 protein; [BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACACA mRNA; [BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACLY mRNA; [BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of FASN mRNA; [BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of SLC5A5 mRNA; [BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TG mRNA; [BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TPO mRNA; [BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TSHR mRNA; [BRAF protein mutant form affects the susceptibility to Vemurafenib] which results in decreased expression of TNFRSF10B protein; [BRAF protein mutant form affects the susceptibility to Vemurafenib] which results in decreased phosphorylation of MAPK1 protein; [BRAF protein mutant form affects the susceptibility to Vemurafenib] which results in decreased phosphorylation of MAPK3 protein; [BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in decreased expression of CD70 protein; [BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in decreased phosphorylation of MAPK1 protein; [BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in decreased phosphorylation of MAPK3 protein; [BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in increased expression of BBC3 protein; [BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in increased expression of BCL2L11 protein; [MET protein affects the susceptibility to HGF protein] affects the reaction [[BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in increased expression of BBC3 protein]; [MET protein affects the susceptibility to HGF protein] affects the reaction [[BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in increased expression of BCL2L11 protein]; [MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]; A-1155463 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]]; ABT-737 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]]; betulin affects the reaction [BRAF protein affects the reaction [Vemurafenib results in decreased cleavage of SREBF1 protein]]; betulin affects the reaction [BRAF protein affects the susceptibility to Vemurafenib]; BRAF protein affects the reaction [Vemurafenib results in decreased cleavage of SREBF1 protein]; BRAF protein affects the reaction [Vemurafenib results in decreased expression of CD70 protein]; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of SLC5A5 mRNA]; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA]; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA]; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TSHR mRNA]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of SLC5A5 mRNA]]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA]]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA]]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TSHR mRNA]]; BRAF protein mutant form inhibits the reaction [Vemurafenib results in increased phosphorylation of MAPK1 protein]; BRAF protein mutant form inhibits the reaction [Vemurafenib results in increased phosphorylation of MAPK3 protein]; CCND1 protein inhibits the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]; fatostatin affects the reaction [BRAF protein affects the reaction [Vemurafenib results in decreased cleavage of SREBF1 protein]]; fatostatin affects the reaction [BRAF protein affects the susceptibility to Vemurafenib]; MAPK1 protein modified form inhibits the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]; MAPK3 protein modified form inhibits the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the cleavage of SREBF1 protein]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACACA mRNA]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACLY mRNA]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of FASN mRNA]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the phosphorylation of MAPK1 protein]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the phosphorylation of MAPK3 protein]; Vemurafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of BRAF protein]; Vemurafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of MAPK1 protein]; Vemurafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of MAPK3 protein]; Vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to Vemurafenib] affects the reaction [TSHB protein affects the expression of SLC5A5 mRNA]]; Vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of SLC5A5 mRNA]; Vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TG mRNA]; Vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TPO mRNA]; Vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TSHR mRNA] BRAF gene mutant form results in increased susceptibility to vemurafenib; BRAF protein mutant form results in increased susceptibility to vemurafenib BRAF protein affects the susceptibility to Vemurafenib; BRAF protein mutant form affects the susceptibility to Vemurafenib
[KRAS protein mutant form affects the susceptibility to Vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]]
[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]]
vemurafenib results in increased secretion of CCL2 protein CCL2 protein results in decreased susceptibility to vemurafenib vemurafenib results in increased expression of CCL2 mRNA
CCND1 protein inhibits the reaction [BRAF protein mutant form results in increased susceptibility to vemurafenib] vemurafenib results in decreased expression of CCND1 protein
vemurafenib results in decreased expression of CD70 protein [BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in decreased expression of CD70 protein; BRAF protein affects the reaction [vemurafenib results in decreased expression of CD70 protein]
[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of DDIT3 protein; DDIT3 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein]
[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of ELK1 protein; ELK1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein]
[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of FASN mRNA; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of FASN mRNA]
[MET protein affects the susceptibility to HGF protein] affects the reaction [[BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BBC3 protein]; [MET protein affects the susceptibility to HGF protein] affects the reaction [[BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BCL2L11 protein]; [MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to vemurafenib]; A-1155463 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to vemurafenib]]; ABT-737 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to vemurafenib]]
KRAS protein mutant form affects the susceptibility to vemurafenib [KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]; [KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]; [KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]; [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of DDIT3 protein; [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of ERN1 protein; [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of HSPA5 protein; [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B mRNA; [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein; [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of ELK1 protein; [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK1 protein; [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK3 protein; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK1 protein]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK3 protein]; AZD 6244 inhibits the reaction [KRAS protein mutant form affects the susceptibility to vemurafenib]; Dactinomycin inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B mRNA]; DDIT3 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein]; ELK1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein]; MAPK1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein]; MAPK3 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK1 protein]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK3 protein]; vemurafenib promotes the reaction [KRAS protein mutant form results in increased expression of TNFRSF10B mRNA]; vemurafenib promotes the reaction [KRAS protein mutant form results in increased expression of TNFRSF10B protein]; vemurafenib promotes the reaction [KRAS protein mutant form results in increased phosphorylation of MAPK1 protein]; vemurafenib promotes the reaction [KRAS protein mutant form results in increased phosphorylation of MAPK3 protein]
[BRAF protein mutant form affects the susceptibility to Vemurafenib] which results in decreased phosphorylation of MAPK1 protein; [BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in decreased phosphorylation of MAPK1 protein; [KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK1 protein; [NRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK1 protein; [YAP1 protein mutant form results in decreased susceptibility to Vemurafenib] inhibits the reaction [Vemurafenib results in decreased phosphorylation of MAPK1 protein]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK1 protein]; BRAF protein mutant form inhibits the reaction [Vemurafenib results in increased phosphorylation of MAPK1 protein]; MAPK1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased expression of TNFRSF10B protein]; MAPK1 protein modified form inhibits the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK1 protein]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the phosphorylation of MAPK1 protein]; Vemurafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of MAPK1 protein]; Vemurafenib promotes the reaction [KRAS protein mutant form results in increased phosphorylation of MAPK1 protein] vemurafenib results in decreased phosphorylation of MAPK1 protein vemurafenib results in increased phosphorylation of MAPK1 protein
vemurafenib results in decreased phosphorylation of MAPK3 protein [BRAF protein mutant form affects the susceptibility to Vemurafenib] which results in decreased phosphorylation of MAPK3 protein; [BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in decreased phosphorylation of MAPK3 protein; [KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK3 protein; [NRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK3 protein; [YAP1 protein mutant form results in decreased susceptibility to Vemurafenib] inhibits the reaction [Vemurafenib results in decreased phosphorylation of MAPK3 protein]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK3 protein]; BRAF protein mutant form inhibits the reaction [Vemurafenib results in increased phosphorylation of MAPK3 protein]; MAPK3 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased expression of TNFRSF10B protein]; MAPK3 protein modified form inhibits the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK3 protein]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the phosphorylation of MAPK3 protein]; Vemurafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of MAPK3 protein]; Vemurafenib promotes the reaction [KRAS protein mutant form results in increased phosphorylation of MAPK3 protein] vemurafenib results in increased phosphorylation of MAPK3 protein
[MET protein affects the susceptibility to HGF protein] affects the reaction [[BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BBC3 protein]; [MET protein affects the susceptibility to HGF protein] affects the reaction [[BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BCL2L11 protein]; [MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to vemurafenib]; A-1155463 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to vemurafenib]]; ABT-737 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to vemurafenib]]
vemurafenib results in decreased expression of MYC protein (+)-JQ1 compound promotes the reaction [vemurafenib results in decreased expression of MYC protein]; [YAP1 protein mutant form results in decreased susceptibility to vemurafenib] inhibits the reaction [vemurafenib results in decreased expression of MYC protein]; vemurafenib promotes the reaction [(+)-JQ1 compound results in decreased expression of MYC protein]
NRAS protein mutant form affects the susceptibility to vemurafenib [NRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein; [NRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK1 protein; [NRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK3 protein
[KRAS protein mutant form affects the susceptibility to Vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]; [Vemurafenib co-treated with 3,5-bis((4-nitrophenyl)methylidene)-1-prop-2-enoylpiperidin-4-one] results in increased cleavage of PARP1 protein; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]]
RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased expression of TNFRSF10B protein]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK1 protein]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK3 protein]
[BRAF protein mutant form affects the susceptibility to vemurafenib] which affects the expression of SLC5A5 mRNA; [TSHB protein co-treated with vemurafenib] affects the expression of SLC5A5 mRNA; [vemurafenib co-treated with vorinostat] results in increased expression of SLC5A5 protein; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with vemurafenib] affects the expression of SLC5A5 mRNA]; BRAF protein mutant form affects the reaction [vorinostat affects the reaction [[TSHB protein co-treated with vemurafenib] affects the expression of SLC5A5 mRNA]]; TSHB protein promotes the reaction [[vemurafenib co-treated with vorinostat] results in increased expression of SLC5A5 protein]; vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to vemurafenib] affects the reaction [TSHB protein affects the expression of SLC5A5 mRNA]]; vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to vemurafenib] which affects the expression of SLC5A5 mRNA]; vorinostat affects the reaction [[TSHB protein co-treated with vemurafenib] affects the expression of SLC5A5 mRNA]
Vemurafenib results in decreased cleavage of SREBF1 protein Vemurafenib results in decreased expression of SREBF1 mRNA alternative form [BRAF protein affects the susceptibility to Vemurafenib] which affects the cleavage of SREBF1 protein; betulin affects the reaction [BRAF protein affects the reaction [Vemurafenib results in decreased cleavage of SREBF1 protein]]; BRAF protein affects the reaction [Vemurafenib results in decreased cleavage of SREBF1 protein]; fatostatin affects the reaction [BRAF protein affects the reaction [Vemurafenib results in decreased cleavage of SREBF1 protein]]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the cleavage of SREBF1 protein]
[BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TG mRNA; [TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA]]; Vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TG mRNA]; Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA]
[BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TPO mRNA; [TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA]]; Vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TPO mRNA]; Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA]
[TSHB protein co-treated with Vemurafenib] affects the expression of SLC5A5 mRNA; [TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA; [TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA; [TSHB protein co-treated with Vemurafenib] affects the expression of TSHR mRNA; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of SLC5A5 mRNA]; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA]; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA]; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TSHR mRNA]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of SLC5A5 mRNA]]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA]]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA]]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TSHR mRNA]]; TSHB protein promotes the reaction [[Vemurafenib co-treated with Vorinostat] results in increased expression of SLC5A5 protein]; Vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to Vemurafenib] affects the reaction [TSHB protein affects the expression of SLC5A5 mRNA]]; Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of SLC5A5 mRNA]; Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA]; Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA]; Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TSHR mRNA]
[BRAF protein mutant form affects the susceptibility to vemurafenib] which affects the expression of TSHR mRNA; [TSHB protein co-treated with vemurafenib] affects the expression of TSHR mRNA; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with vemurafenib] affects the expression of TSHR mRNA]; BRAF protein mutant form affects the reaction [vorinostat affects the reaction [[TSHB protein co-treated with vemurafenib] affects the expression of TSHR mRNA]]; vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to vemurafenib] which affects the expression of TSHR mRNA]; vorinostat affects the reaction [[TSHB protein co-treated with vemurafenib] affects the expression of TSHR mRNA]
[YAP1 protein mutant form results in decreased susceptibility to vemurafenib] inhibits the reaction [vemurafenib results in decreased expression of MYC protein]; [YAP1 protein mutant form results in decreased susceptibility to vemurafenib] inhibits the reaction [vemurafenib results in decreased phosphorylation of MAPK1 protein]; [YAP1 protein mutant form results in decreased susceptibility to vemurafenib] inhibits the reaction [vemurafenib results in decreased phosphorylation of MAPK3 protein] vemurafenib affects the localization of YAP1 protein
browse the term
